Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021

Chang, CC; Blyth, CC; Chen, SCA; Khanina, A; Morrissey, CO; Roberts, JA; Thursky, KA; Worth, LJ; Slavin, MA; Australasian Antifungal Guidelines Steering Committee

Author(s): Chang, CC; Blyth, CC; Chen, SCA; Khanina, A; Morrissey, CO; Roberts, JA; Thursky, KA; Worth, LJ; Slavin, MA; Australasian Antifungal Guidelines Steering Committee;
Details: Publication Year 2021-11,Volume 51,Issue #Suppl 7,Page 3-17
Journal Title: Internal Medicine Journal
Publication Type: Guideline
Abstract: This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings. Given that 7 years have passed since the previous iteration of these guidelines, pertinent contextual changes that impacted guideline content and recommendations are discussed, including the evolution of invasive fungal disease (IFD) definitions. We also outline our approach to guideline development, evidence grading, review and feedback. Highlights of the 2021 update are presented, including expanded scope to provide more detailed coverage of common and emerging fungi such as Aspergillus and Candida species, and emerging fungi, and a greater focus on the principles of antifungal stewardship. We also introduce an entirely new chapter dedicated to helping healthcare workers convey important concepts related to IFD, infection prevention and antifungal therapy, to patients.
Keywords: Antifungal Agents/therapeutic use; Australia; *Hematology; Humans; *Invasive Fungal Infections/drug therapy/microbiology; Medical Oncology; Aspergillus; antifungal prophylaxis; antifungal therapy; haematological malignancy; invasive fungal disease; treatment guideline
Department(s): Infectious Diseases
PubMed ID: 34937135
Publisher's Version: https://doi.org/10.1111/imj.15585
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-06-20 08:03:14

Last Modified: 2025-06-20 08:04:25